- Conditions
- Breast Cancer
- Interventions
- Ribociclib
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 472
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma
- Interventions
- Nivolumab, Hydroxychloroquine, Ipilimumab
- Drug
- Lead sponsor
- Ravi Amaravadi, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Immune Reconstitution Inflammatory Syndrome, HIV, HIV Infections
- Interventions
- maraviroc, Placebo
- Drug
- Lead sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 4
- States / cities
- Bethesda, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Influenza
- Interventions
- Amantadine, Ribavirin, Oseltamivir, Oseltamivir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 58 more
- Conditions
- Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
- Interventions
- Etoposide, Interferon-alpha, Rituximab, Zidovudine, Liposomal Doxorubicin, Bortezomib, Valganciclovir, Doxorubicin, Vincristine, Cyclophosphamide, Filgrastim (G-CSF), Prednisone, Sirolimus, Observation Only
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Enzalutamide, EPI-7386 with Enzalutamide
- Drug
- Lead sponsor
- ESSA Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Port Saint Lucie, Florida • Tampa, Florida + 8 more
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- tipifarnib, etoposide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 70 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
- Conditions
- Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
- Interventions
- Envafolimab, Ipilimumab
- Biological · Drug
- Lead sponsor
- Tracon Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Los Angeles, California • Santa Monica, California + 22 more
- Conditions
- Neuroblastoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Liposarcoma
- Interventions
- Silmitasertib, Irinotecan, Temozolomide, Vincristine
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2035
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 20 more
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- X4P-001, axitinib
- Drug
- Lead sponsor
- X4 Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 15 more
- Conditions
- HIV-1 Infection, Hepatitis
- Interventions
- Sofosbuvir, Ribavirin, Ledipasvir/Sofosbuvir
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 12
- States / cities
- San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more
- Conditions
- HIV-1 Infection
- Interventions
- Pravastatin sodium, Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Torrance, California • St Louis, Missouri + 6 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- CT-011, FOLFOX
- Drug
- Lead sponsor
- Medivation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 5
- States / cities
- Huntsville, Alabama • Tampa, Florida • New York, New York + 2 more
- Conditions
- Schizophrenia, Negative Type; Schizophrenic, Schizo Affective Disorder
- Interventions
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Device
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hepatitis C
- Interventions
- BMS-650032, BMS-790052
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Cystic Fibrosis
- Interventions
- TEZ, IVA, VX-440, Matched Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab, Tiragolumab, Matching Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 9
- States / cities
- Denver, Colorado • New Haven, Connecticut • St. Petersburg, Florida + 6 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Nelfinavir mesylate, Efavirenz
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more
- Conditions
- Hepatitis C, HIV Infections
- Interventions
- Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Richmond, Virginia
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 12
- States / cities
- Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Refametinib (BAY86-9766), Sorafenib (BAY43-9006)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- AML/MDS, CMML, Relapse, Refractory Acute Lymphoblastic Leukemia, Relapse Leukemia, Relapsed Adult AML
- Interventions
- LP-108, LP-108 and azacitidine
- Drug
- Lead sponsor
- Newave Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Ann Arbor, Michigan • Cincinnati, Ohio • Columbus, Ohio + 1 more
- Conditions
- Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)
- Interventions
- Tirapazamine, Cisplatin, 5-fluorouracil, Radiotherapy (RT)
- Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 17 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Stanford, California